Navigation Links
Plavix Gets FDA Okay for New Indication

The antiplatelet medication Plavix (clopidogrel bisulfate) received US Food and Drug Administration approval for use in acute coronary syndrome. People with acute coronary syndrome are at high risk for heart attack, typically because they have unstable angina, or heart disease-related chest pain. About 1.1 to 1.4 million Americans experience acute coronary syndrome each year.//

Plavix was first approved in 1997 for patients with a recent heart attack, stroke or peripheral artery disease. It is marketed worldwide by Bristol-Myers Squibb and Sanofi-Synthelabo. Plavix reduces the "stickiness" of platelets, a type of cell that plays a key role in blood clot formation. It is usually given in addition to aspirin.

To get FDA approval for acute coronary syndrome, Bristol-Myers submitted data from a trial that was published in The New England Journal of Medicine. In that study, Plavix reduced the risk of heart attack, stroke or cardiovascular death by 20% in acute coronary syndrome patients, when compared with placebo.
'"/>




Page: 1

Related medicine news :

1. Sanofi-Aventis Allows Thais To Make Plavix
2. Plavix Safe During and After Heart Bypass
3. Hiccups May Be An Indication Of Esophageal Cancer
4. ADHD Drugs To Have Warnings On Contra Indications
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Plavix Gets FDA Okay for New Indication

Breaking Medicine Technology:Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 2Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 3Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 4FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 52 Springer authors receive NWO Spinoza Prize in the Netherlands 12777 1AAHSA Statement on House Ways and Means Committee Hearing 49988 1AAHSA Statement on House Ways and Means Committee Hearing 49988 2U S Womens Chamber of Commerce Advocates Strong Healthcare Reforms in Support of American Values 49985 1U S Womens Chamber of Commerce Advocates Strong Healthcare Reforms in Support of American Values 49985 2